Allianz Asset Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.56M | Buy |
543,781
+74,215
| +16% | +$621K | ﹤0.01% | 1428 |
|
|
2026
Q1 | $3.9M | Buy |
469,566
+178,865
| +62% | +$1.85M | ﹤0.01% | 1273 |
|
|
2025
Q4 | $3.59M | Buy |
290,701
+10,894
| +4% | +$117K | ﹤0.01% | 1297 |
|
|
2025
Q3 | $2.47M | Buy |
279,807
+167,423
| +149% | +$1.3M | ﹤0.01% | 1418 |
|
|
2025
Q2 | $717K | Buy |
+112,384
| New | +$643K | ﹤0.01% | 1747 |
|
|
2023
Q3 | – | Sell |
-290,700
| Closed | -$2.14M | – | 2205 |
|
|
2023
Q2 | $2.14M | Buy |
290,700
+244,057
| +523% | +$2.26M | ﹤0.01% | 1249 |
|
|
2023
Q1 | $483K | Buy |
46,643
+1,500
| +3% | +$18.1K | ﹤0.01% | 1908 |
|
|
2022
Q4 | $533K | Buy |
+45,143
| New | +$699K | ﹤0.01% | 1712 |
|
|
2022
Q1 | – | Sell |
-22,984
| Closed | -$999K | – | 2461 |
|
|
2021
Q4 | $999K | Sell |
22,984
-10,396
| -31% | -$470K | ﹤0.01% | 1914 |
|
|
2021
Q3 | $1.67M | Buy |
33,380
+9,605
| +40% | +$582K | ﹤0.01% | 1717 |
|
|
2021
Q2 | $1.5M | Buy |
23,775
+903
| +4% | +$58K | ﹤0.01% | 1577 |
|
|
2021
Q1 | $2.13M | Buy |
22,872
+6,260
| +38% | +$641K | ﹤0.01% | 1379 |
|
|
2020
Q4 | $1.49M | Sell |
16,612
-20,606
| -55% | -$1.89M | ﹤0.01% | 1386 |
|
|
2020
Q3 | $3.85M | Buy |
37,218
+902
| +2% | +$97.2K | ﹤0.01% | 1063 |
|
|
2020
Q2 | $2.87M | Buy |
36,316
+700
| +2% | +$52.2K | ﹤0.01% | 1453 |
|
|
2020
Q1 | $2.06M | Buy |
35,616
+18,412
| +107% | +$1.06M | ﹤0.01% | 1516 |
|
|
2019
Q4 | $928K | Buy |
17,204
+262
| +2% | +$14.2K | ﹤0.01% | 2235 |
|
|
2019
Q3 | $885K | Sell |
16,942
-4,046
| -19% | -$188K | ﹤0.01% | 2175 |
|
|
2019
Q2 | $1.01M | Sell |
20,988
-97,726
| -82% | -$4.68M | ﹤0.01% | 2132 |
|
|
2019
Q1 | $6M | Buy |
118,714
+19,115
| +19% | +$1.13M | 0.01% | 1370 |
|
|
2018
Q4 | $5.9M | Sell |
99,599
-3,009
| -3% | -$194K | 0.01% | 1338 |
|
|
2018
Q3 | $6.75M | Sell |
102,608
-2,064
| -2% | -$120K | 0.01% | 1425 |
|
|
2018
Q2 | $5.29M | Sell |
104,672
-8,186
| -7% | -$427K | 0.01% | 1498 |
|
|
2018
Q1 | $5.94M | Buy |
112,858
+42,728
| +61% | +$2.13M | 0.01% | 1465 |
|
|
2017
Q4 | $3.26M | Buy |
70,130
+2,217
| +3% | +$93.3K | ﹤0.01% | 1812 |
|
|
2017
Q3 | $2.75M | Sell |
67,913
-290
| -0.4% | -$10.5K | ﹤0.01% | 1890 |
|
|
2017
Q2 | $2.31M | Sell |
68,203
-8,577
| -11% | -$265K | ﹤0.01% | 1928 |
|
|
2017
Q1 | $2.23M | Hold |
76,780
| – | – | ﹤0.01% | 1954 |
|
|
2016
Q4 | $2.52M | Sell |
76,780
-75,254
| -49% | -$2.26M | ﹤0.01% | 1879 |
|
|
2016
Q3 | $4.22M | Buy |
152,034
+58,547
| +63% | +$1.7M | ﹤0.01% | 1690 |
|
|
2016
Q2 | $2.63M | Sell |
93,487
-50,145
| -35% | -$1.97M | ﹤0.01% | 1805 |
|
|
2016
Q1 | $5.22M | Buy |
143,632
+123,446
| +612% | +$4.36M | 0.01% | 1427 |
|
|
2015
Q4 | $813K | Buy |
20,186
+1,442
| +8% | +$50.3K | ﹤0.01% | 2052 |
|
|
2015
Q3 | $534K | Sell |
18,744
-188
| -1% | -$6.2K | ﹤0.01% | 2031 |
|
|
2015
Q2 | $624K | Sell |
18,932
-1,341
| -7% | -$41.6K | ﹤0.01% | 2088 |
|
|
2015
Q1 | $583K | Sell |
20,273
-21,564
| -52% | -$618K | ﹤0.01% | 1947 |
|
|
2014
Q4 | $1.14M | Buy |
41,837
+1,600
| +4% | +$38.1K | ﹤0.01% | 1781 |
|
|
2014
Q3 | $857K | Buy |
40,237
+21,089
| +110% | +$483K | ﹤0.01% | 1712 |
|
|
2014
Q2 | $430K | Sell |
19,148
-93,388
| -83% | -$2.18M | ﹤0.01% | 1614 |
|
|
2014
Q1 | $2.84M | Buy |
+112,536
| New | +$2.84M | ﹤0.01% | 1100 |
|
Other funds holding EBS
OHA
Allianz Asset Management's EBS Position: Q2 2026 in Review
Allianz Asset Management increased its Emergent Biosolutions (EBS) stake by 16% in Q2 2026, buying an estimated $621K and bringing the position to 543,781 shares worth $4.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1428.
Allianz Asset Management first reported a position in EBS in Q1 2014 and has held it in 40 quarters since. The position peaked at $6.75M in Q3 2018. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.
- Allianz Asset Management held 543,781 shares of Emergent Biosolutions worth $4.56M as of Q2 2026.
- Allianz Asset Management bought 74,215 Emergent Biosolutions shares in Q2 2026, an estimated $621K.
- Emergent Biosolutions made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1428 holding.
- Allianz Asset Management first reported a position in Emergent Biosolutions in Q1 2014 and has held it in 40 quarters since.
- Allianz Asset Management's Emergent Biosolutions position peaked at $6.75M in Q3 2018.
- 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.
Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.